TG Therapeutics (TGTX)

Executive Summary

TG Therapeutics is a commercial-stage biopharmaceutical company focused on glycoengineered monoclonal antibodies for B-cell mediated diseases. The company's lead product, BRIUMVI® (ublituximab), received FDA approval for relapsing forms of multiple sclerosis (RMS) and is driving revenue growth. With a single approved product, TG Therapeutics is working to expand BRIUMVI's label and advance its pipeline, which includes earlier-stage candidates for hematologic malignancies. The company's commercial infrastructure is established, but its near-term growth depends on successful market penetration and potential label expansions. Financially, TG Therapeutics has a market cap of ~$6.2B, reflecting investor optimism about BRIUMVI's commercial potential and pipeline prospects. However, the company faces competition from established MS therapies and must demonstrate sustained execution to maintain valuation. Key priorities include driving BRIUMVI adoption, exploring combination therapies, and advancing earlier-stage pipeline assets. The company's conviction score is moderate, reflecting commercial validation but limited pipeline diversification beyond its core MS franchise.

Upcoming Catalysts (preview)

• Q4 2026BRIUMVI label expansion for additional MS indications or new data from ongoing Phase 3 trial (NCT05877963)60% success
• H1 2027Potential partnership or licensing deal for pipeline assets (e.g., ublituximab combinations in oncology)40% success
• Q3 2026Announcement of BRIUMVI quarterly sales exceeding consensus estimates70% success